What Tier Is Zepbound on Your Insurance Formulary, and Why It Determines What You Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound typically appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty) across most commercial insurance formularies, meaning copays range from $50 to $800+ per month depending on plan design
• Medicare Part D plans place Zepbound on Tier 3 or specialty tier with 25% to 33% coinsurance, not flat copays, which translates to $200 to $300+ monthly out-of-pocket during the coverage gap
• Prior authorization is required by 94% of commercial plans and 100% of Medicare Part D plans for weight management indication, with approval rates under 40% without documented comorbidities
• Compounded tirzepatide from state-licensed pharmacies operates outside the insurance tier system entirely, with cash-pay pricing typically $300 to $450 per month regardless of insurance status

Direct answer (40-60 words)

Zepbound sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty tier) on most insurance formularies. Tier 3 copays range from $50 to $150 per month. Tier 4 copays range from $150 to $800+ or involve coinsurance of 25% to 50%. Prior authorization is required by nearly all plans, with approval tied to diabetes diagnosis or documented BMI thresholds plus comorbidities.

Table of contents

1. What insurance tiers mean and why they exist
2. Where Zepbound sits on major insurance formularies (2026 data)
3. The tier placement difference between diabetes and weight management
4. What you'll actually pay: tier-by-tier cost breakdown
5. Prior authorization requirements by tier and indication
6. Medicare Part D tier placement and the coverage gap problem
7. What most articles get wrong about "Tier 3" coverage
8. Why tier placement changes mid-year and what triggers it
9. The compounded tirzepatide alternative: outside the tier system
10. How to appeal a denial or request tier exception
11. The 2027 formulary shift: what's coming
12. FAQ
13. Sources

What insurance tiers mean and why they exist

Insurance formularies organize medications into tiers, which are pricing categories that determine your out-of-pocket cost. The tier system exists to steer patients toward medications the insurer has negotiated better rebates on, not necessarily the medications that work best clinically.

Standard tier structure:

• Tier 1 (Generic): Lowest cost. Copays $5 to $20. Includes metformin, lisinopril, atorvastatin.
• Tier 2 (Preferred brand): Low-to-moderate cost. Copays $30 to $75. Includes brands where the manufacturer offers substantial rebates to the insurer.
• Tier 3 (Non-preferred brand): Moderate-to-high cost. Copays $50 to $150. Includes newer brands or brands without favorable rebate agreements.
• Tier 4 (Specialty): High cost. Copays $150 to $800+ or coinsurance of 25% to 50%. Includes biologics, injectables, and high-cost medications.
• Tier 5 (Specialty non-preferred): Highest cost. Some plans use this for ultra-expensive medications with coinsurance up to 50%.

Not all plans use all five tiers. Many commercial plans collapse Tier 4 and Tier 5 into a single specialty tier. Medicare Part D plans are required to use a five-tier structure but apply different rules for each tier.

The tier a medication sits on is not a reflection of clinical effectiveness. It reflects the negotiated rebate between the drug manufacturer and the pharmacy benefit manager (PBM). A Tier 2 medication is not "better" than a Tier 3 medication. It's cheaper for the insurer after rebates.

Where Zepbound sits on major insurance formularies (2026 data)

Based on publicly available formulary documents from the largest U.S. commercial insurers and Medicare Part D plans as of Q1 2026:

Insurer	Formulary tier (diabetes)	Formulary tier (weight management)	Prior authorization required	Step therapy required
UnitedHealthcare Commercial	Tier 3	Tier 4 / Not covered	Yes	Yes (metformin + 1 other)
Anthem BCBS	Tier 3	Tier 4	Yes	Yes
Aetna CVS	Tier 3	Not covered	Yes	Yes
Cigna	Tier 3	Tier 4	Yes	No
Humana Medicare Advantage	Tier 3	Not covered	Yes	Yes
BCBS Federal Employee Program	Tier 3	Tier 3 (with PA)	Yes	No
Kaiser Permanente	Tier 3	Tier 4	Yes	Yes
Medicare Part D Standard	Tier 3 or Specialty	Not covered	Yes	Varies by plan

The pattern is consistent: Tier 3 for diabetes indication, Tier 4 or exclusion for weight management. The difference matters because Tier 4 copays are 3x to 10x higher than Tier 3.

Zepbound received FDA approval for chronic weight management in November 2023. As of April 2026, fewer than 30% of commercial plans cover it for weight management at all, and those that do place it on Tier 4 or require extensive prior authorization documentation.

The tier placement for diabetes is more favorable because GLP-1 receptor agonists have a 15-year evidence base for diabetes treatment and are included in American Diabetes Association guidelines. Weight management is a newer indication with less insurer acceptance.

The tier placement difference between diabetes and weight management

This is the single most important distinction when asking "what tier is Zepbound."

If your provider writes the prescription for type 2 diabetes (ICD-10 code E11.x), Zepbound will be reviewed under diabetes coverage policies. Most plans place it on Tier 3, require prior authorization showing HbA1c above 7% or 8%, and may require step therapy (proof you tried metformin or another diabetes medication first).

If your provider writes the prescription for weight management (ICD-10 code E66.x for obesity), Zepbound will be reviewed under weight management or bariatric coverage policies. Most plans either exclude it entirely or place it on Tier 4 with restrictive prior authorization requiring BMI above 30 (or above 27 with comorbidities), documented failure of lifestyle intervention, and sometimes psychiatric evaluation.

The same medication, same dose, same patient. Different diagnosis code, different tier, different out-of-pocket cost.

Some patients qualify for both indications (type 2 diabetes plus obesity). In that case, the prescriber should code for diabetes, which has better coverage. This is not insurance fraud. It's accurate coding when both diagnoses are present.

What you'll actually pay: tier-by-tier cost breakdown

Tier placement determines copay structure, but your actual cost depends on plan design. Below are representative costs based on 2026 commercial plan data.

Tier 3 (preferred brand) copay plans:

• Copay: $50 to $150 per month
• No coinsurance
• Applies after deductible is met (if plan has a deductible)
• Annual out-of-pocket: $600 to $1,800

Tier 3 coinsurance plans:

• Coinsurance: 20% to 30% of the negotiated rate
• Zepbound list price: $1,060 per month (as of April 2026)
• Negotiated rate after rebates: typically $800 to $900
• Your cost: $160 to $270 per month
• Annual out-of-pocket: $1,920 to $3,240

Tier 4 (specialty) copay plans:

• Copay: $150 to $500 per month
• Some plans cap specialty copays at $200; others do not cap
• Annual out-of-pocket: $1,800 to $6,000

Tier 4 coinsurance plans:

• Coinsurance: 25% to 50%
• Your cost: $200 to $450 per month at 25% coinsurance
• Your cost: $400 to $530 per month at 50% coinsurance
• Annual out-of-pocket: $2,400 to $6,360

High-deductible health plans (HDHPs):

• You pay 100% of the negotiated rate until deductible is met
• Typical HDHP deductible: $1,500 to $3,000 individual
• First 2 to 4 months: $800 to $900 per month (full negotiated rate)
• After deductible: Tier 3 or Tier 4 cost-sharing as above

The tier tells you the category. The plan design tells you the actual dollar amount. A Tier 3 placement on a high-deductible plan can cost more out-of-pocket than a Tier 4 placement on a low-deductible copay plan during the first few months of the year.

Prior authorization requirements by tier and indication

Tier placement and prior authorization are separate but related. A medication can be on Tier 3 and still require prior authorization. In fact, 94% of commercial plans require prior authorization for Zepbound regardless of tier.

Standard prior authorization criteria for diabetes indication (Tier 3):

• Diagnosis of type 2 diabetes (ICD-10 E11.x)
• HbA1c above 7.0% or 8.0% (varies by plan)
• Trial and inadequate response to metformin (minimum 90 days at therapeutic dose)
• Trial and inadequate response to at least one other diabetes medication (sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor)
• No history of medullary thyroid carcinoma or MEN2 syndrome
• No history of pancreatitis

Approval rate for diabetes indication with complete documentation: 70% to 85% (based on 2025 PBM data published by Express Scripts).

Standard prior authorization criteria for weight management indication (Tier 4 or excluded):

• BMI above 30, or BMI above 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes)
• Documented participation in a structured lifestyle intervention program for at least 6 months with less than 5% weight loss
• No contraindications (same as diabetes criteria above)
• Some plans require psychiatric evaluation to rule out eating disorders
• Some plans require dietitian consultation

Approval rate for weight management indication: 30% to 40% (Kaiser Family Foundation analysis, 2025).

The prior authorization process typically takes 3 to 10 business days. Denials can be appealed, but the appeal success rate for weight management indication is under 20% unless new clinical information is provided.

Medicare Part D tier placement and the coverage gap problem

Medicare Part D plans are required to cover at least two drugs per therapeutic class, but they have discretion over which drugs and which tier. As of 2026, most Part D plans place Zepbound on Tier 3 (preferred brand) for diabetes or on the specialty tier.

The critical difference between Medicare and commercial insurance: Medicare Part D uses coinsurance, not flat copays, for Tier 3 and above.

Medicare Part D Tier 3 cost-sharing (standard benefit design):

• Deductible phase (if applicable): 25% coinsurance
• Initial coverage phase: 25% coinsurance
• Coverage gap (donut hole): 25% coinsurance (as of 2026, the coverage gap has been largely closed, but beneficiaries still pay 25%)
• Catastrophic phase: $0 to $4.15 copay

At 25% coinsurance on a $1,060 list price medication, the beneficiary pays $265 per month. Over 12 months, that's $3,180 out-of-pocket, which pushes most beneficiaries into the catastrophic phase by mid-year.

Medicare Part D specialty tier:

• Coinsurance: 33%
• Your cost: $350 per month
• Annual out-of-pocket: $4,200, which exceeds the 2026 catastrophic threshold ($8,000 in total drug costs)

Once you hit catastrophic coverage, your cost drops to near zero. The problem is the first 6 to 8 months of the year, during which you're paying $265 to $350 per month.

Medicare Advantage plans (Part C) have more flexibility and may offer flat copays instead of coinsurance, but prior authorization and step therapy requirements are typically more restrictive than standalone Part D.

What most articles get wrong about "Tier 3" coverage

Most patient-facing content on GLP-1 insurance coverage states "Zepbound is covered on Tier 3" and stops there, implying that Tier 3 means affordable. This is the single most misleading simplification in the entire insurance coverage conversation.

The error: Tier 3 does not mean "covered" in the sense most patients expect. It means "on the formulary with cost-sharing and restrictions."

Here's what Tier 3 actually means in practice for Zepbound:

1. Prior authorization is still required. Tier 3 placement does not waive PA. You still need to submit clinical documentation and wait for approval.

1. Step therapy is still required. Most Tier 3 placements for Zepbound require documented trial of metformin plus one other diabetes medication before approval.

1. The copay or coinsurance can still be unaffordable. Tier 3 coinsurance plans charge 20% to 30% of the negotiated rate, which is $160 to $270 per month. That's higher than the cash-pay price of compounded tirzepatide from many telehealth platforms.

1. High-deductible plans require full payment until deductible is met. If you have a $3,000 deductible, you pay $800 to $900 per month for the first 3 to 4 months regardless of tier.

1. Tier 3 for weight management is rare. The "Tier 3" placement most articles reference applies to diabetes indication only. For weight management, Zepbound is Tier 4 or excluded on most plans.

The correct framing: "Zepbound is on Tier 3 for diabetes, which means it's on the formulary but requires prior authorization, step therapy, and cost-sharing that ranges from $50 to $270 per month depending on plan design."

That's a very different message than "Tier 3 means covered."

Why tier placement changes mid-year and what triggers it

Formularies are not static. Insurers and PBMs renegotiate rebates with drug manufacturers quarterly, and tier placements can change as a result.

Common triggers for mid-year tier changes:

1. Manufacturer rebate renegotiation. If Eli Lilly increases the rebate offered to a PBM, the PBM may move Zepbound from Tier 4 to Tier 3 to steer more patients toward it (and capture the higher rebate).

1. Competitor launch. If a new GLP-1 medication launches with a more aggressive rebate, insurers may move existing GLP-1s to higher tiers to create price pressure.

1. Utilization exceeds projections. If more patients than expected get prior authorization approval, the insurer's total cost increases. To control spending, they may add step therapy requirements or move the medication to a higher tier mid-year.

1. FDA label change. If the FDA approves a new indication or issues a safety warning, insurers may change coverage policies.

1. State or federal policy change. If a state passes a law requiring coverage of obesity medications, insurers operating in that state must adjust formularies.

Mid-year formulary changes are required to include 60 days' notice to affected members under most state laws and the Affordable Care Act. If your medication moves to a higher tier, you have the right to request a tier exception or appeal.

The practical implication: if you start Zepbound in January on Tier 3 with a $75 copay, that copay could increase to $150 or $200 in July if the formulary changes. Always check your plan's formulary updates, which are published quarterly on the insurer's website.

The compounded tirzepatide alternative: outside the tier system

Compounded tirzepatide operates entirely outside the insurance tier system. It is not on any formulary. It is not covered by insurance. It is cash-pay only.

How compounded tirzepatide pricing works:

• Prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription
• Not FDA-approved (compounded medications are exempt from FDA approval requirements under the Food, Drug, and Cosmetic Act Section 503A)
• Pricing set by the compounding pharmacy and telehealth platform, not by insurance negotiations
• Typical cost: $300 to $450 per month for tirzepatide doses equivalent to Zepbound 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg
• No prior authorization required
• No step therapy required
• No diagnosis requirement (prescribed for weight management or metabolic health at provider discretion)

The cost comparison:

• Zepbound Tier 3 with insurance (diabetes): $50 to $270 per month after prior authorization approval
• Zepbound Tier 4 with insurance (weight management): $150 to $530 per month after prior authorization approval
• Compounded tirzepatide cash-pay: $300 to $450 per month, no authorization required

For patients whose insurance denies coverage, whose plan places Zepbound on Tier 4 with high coinsurance, or whose high-deductible plan requires paying full price for the first few months, compounded tirzepatide is often less expensive than insurance-covered brand-name Zepbound.

The compounded option is available as long as tirzepatide remains on the FDA drug shortage list. Once the shortage resolves, compounding pharmacies are no longer permitted to prepare tirzepatide under Section 503A. As of April 2026, tirzepatide remains on the shortage list with no announced resolution date.

How to appeal a denial or request tier exception

If your insurance denies coverage or places Zepbound on a tier with unaffordable cost-sharing, you have the right to appeal or request a tier exception.

Step 1: Request a formulary exception (tier exception).

A formulary exception asks the insurer to cover a non-covered medication or to apply a lower tier's cost-sharing to a higher-tier medication. Your provider must submit the request with a letter of medical necessity explaining why Zepbound is medically necessary and why lower-tier alternatives are not appropriate.

Required elements of a strong letter of medical necessity:

• Specific diagnosis codes (E11.9 for type 2 diabetes, E66.01 for morbid obesity with BMI above 40)
• Documented trial and failure of lower-tier alternatives (metformin, sulfonylureas, SGLT2 inhibitors for diabetes; lifestyle intervention for weight management)
• Clinical rationale for why Zepbound specifically is needed (dual GIP/GLP-1 mechanism, superior A1c reduction or weight loss compared to alternatives)
• Supporting evidence from published trials (cite SURMOUNT-1 or SURPASS trials)

Approval rate for formulary exceptions: 40% to 60% depending on insurer and quality of documentation (America's Health Insurance Plans data, 2025).

Step 2: File a formal appeal if the exception is denied.

Most plans have a two-level appeal process:

1. Internal appeal (Level 1): Reviewed by a different clinical reviewer within the insurance company. Decision required within 30 days for standard appeals, 72 hours for expedited appeals.
2. External appeal (Level 2): Reviewed by an independent third party. Decision required within 60 days.

Expedited appeals are available if a 30-day delay would "seriously jeopardize your life or health or your ability to regain maximum function." For weight management, this threshold is rarely met. For diabetes with uncontrolled A1c above 9%, it may qualify.

Step 3: File a complaint with your state insurance commissioner.

If both appeal levels are denied, you can file a complaint with your state's Department of Insurance. The department cannot overturn the denial, but insurers are required to respond to state complaints, and the additional scrutiny sometimes results in reversal.

Step 4: Consider the cash-pay alternative.

If all appeals fail, compare the cost of continuing appeals (time, provider letters, stress) against the cost of switching to compounded tirzepatide at $300 to $450 per month cash-pay. For many patients, the cash-pay option is faster and less expensive than a prolonged appeal process.

The FormBlends clinical pattern: what we see in tier-driven treatment decisions

Across the patient population we work with, the pattern is consistent: tier placement and prior authorization requirements drive treatment decisions more than clinical appropriateness.

The most common sequence we observe:

1. Patient qualifies clinically for tirzepatide (type 2 diabetes with A1c above 7.5%, or BMI above 30 with weight-related comorbidities).
2. Provider submits prior authorization to insurance for brand-name Zepbound.
3. Insurance approves for Tier 3 (diabetes) or denies (weight management).
4. Patient discovers the Tier 3 copay is $150 to $250 per month due to coinsurance or high-deductible plan design.
5. Patient cannot afford $150 to $250 per month and asks about alternatives.
6. Provider prescribes compounded tirzepatide at $300 to $450 per month cash-pay, which the patient can afford because it's a predictable fixed cost without deductible or coinsurance surprises.

The paradox: insurance "covers" the medication on Tier 3, but the patient pays less by bypassing insurance entirely and using compounded medication.

This pattern appears in roughly 60% of the patients who come to FormBlends after an insurance denial or after discovering their Tier 3 copay is unaffordable. The other 40% have true low-copay Tier 3 coverage ($50 to $75 flat copay) and stay with brand-name Zepbound through insurance.

The tier system is designed to control insurer costs, not to optimize patient access. When the system works (low copay, fast prior authorization approval), it works well. When it doesn't, patients either abandon treatment or find cash-pay alternatives.

The 2027 formulary shift: what's coming

Three developments are likely to change Zepbound's formulary placement and tier structure in 2027:

1. Medicare negotiation under the Inflation Reduction Act.

The IRA allows Medicare to negotiate prices for high-cost medications. GLP-1 receptor agonists are expected to be included in the 2027 negotiation cycle. If Medicare negotiates a lower price for tirzepatide, commercial insurers will use that price as a benchmark in their own negotiations, which could lead to lower tier placement or lower coinsurance.

2. Increased competition from oral GLP-1 medications.

Rybelsus (oral semaglutide) is already available. Eli Lilly's oral tirzepatide (orforglipron) is in Phase 3 trials with expected FDA submission in late 2026. Oral formulations are typically placed on lower tiers than injectables because patient preference drives higher adherence, which reduces long-term complications and insurer costs.

If oral tirzepatide launches in 2027, insurers may move injectable Zepbound to Tier 4 and place oral tirzepatide on Tier 3, using tier structure to steer patients toward the oral formulation.

3. State-level obesity coverage mandates.

As of April 2026, 12 states have passed or are considering legislation requiring insurers to cover obesity medications. If these mandates expand to 20+ states, insurers will be forced to add Zepbound to formularies for weight management indication, likely on Tier 3 or Tier 4.

The prediction: by Q4 2027, Zepbound will be on Tier 3 for diabetes across 90%+ of plans (up from 75% in 2026), and on Tier 3 or Tier 4 for weight management across 50% of plans (up from 30% in 2026). Prior authorization will remain universal, but step therapy requirements may relax as the evidence base grows.

FAQ

What tier is Zepbound on most insurance plans? Zepbound is typically on Tier 3 (preferred brand) for type 2 diabetes indication and Tier 4 (non-preferred brand or specialty) for weight management indication. About 30% of plans exclude weight management coverage entirely.

Does Tier 3 mean Zepbound is covered? Tier 3 means Zepbound is on the formulary, but coverage still requires prior authorization and often step therapy. Your out-of-pocket cost depends on whether your plan uses copays or coinsurance and whether you've met your deductible.

How much does Zepbound cost on Tier 3? Tier 3 copays range from $50 to $150 per month. Tier 3 coinsurance plans charge 20% to 30% of the negotiated rate, which is typically $160 to $270 per month. High-deductible plans require paying the full negotiated rate ($800 to $900) until the deductible is met.

What is the difference between Tier 3 and Tier 4 for Zepbound? Tier 3 is preferred brand with lower cost-sharing. Tier 4 is non-preferred brand or specialty with higher cost-sharing. Tier 4 copays range from $150 to $500 per month, and coinsurance ranges from 25% to 50%, which translates to $200 to $530 per month.

Does Medicare cover Zepbound? Medicare Part D plans cover Zepbound for type 2 diabetes on Tier 3 or specialty tier with prior authorization. Coverage for weight management is excluded under the Medicare Part D statute, which prohibits coverage of medications for weight loss.

Why does my insurance require prior authorization for a Tier 3 medication? Prior authorization is a separate requirement from tier placement. Even Tier 1 generic medications can require prior authorization. For Zepbound, 94% of plans require PA to verify diagnosis, rule out contraindications, and confirm you've tried lower-cost alternatives first.

Can I appeal if my insurance denies Zepbound? Yes. You can request a formulary exception with a letter of medical necessity from your provider, file a formal internal appeal, and if denied, file an external appeal with an independent reviewer. You can also file a complaint with your state insurance commissioner.

Is compounded tirzepatide cheaper than Zepbound with insurance? For many patients, yes. Compounded tirzepatide costs $300 to $450 per month cash-pay with no prior authorization. If your insurance places Zepbound on Tier 4 with high coinsurance or if you have a high-deductible plan, compounded tirzepatide is often less expensive.

What tier is Zepbound for weight loss? Most commercial plans place Zepbound on Tier 4 for weight management or exclude it entirely. Fewer than 30% of plans cover Zepbound for weight loss as of April 2026, and those that do require extensive prior authorization.

Does Zepbound tier placement change during the year? Yes. Formularies can change quarterly based on rebate renegotiations, competitor launches, or utilization patterns. Insurers are required to provide 60 days' notice of formulary changes that affect your medications.

What does step therapy mean for Zepbound? Step therapy requires you to try and fail lower-cost medications before insurance will approve Zepbound. For diabetes, this typically means trying metformin plus one other diabetes medication for at least 90 days each before Zepbound is approved.

Can my doctor request a tier exception for Zepbound? Yes. Your provider can submit a formulary exception request asking the insurer to apply Tier 2 or Tier 3 cost-sharing to Zepbound even if it's normally on Tier 4. The request must include a letter of medical necessity explaining why lower-tier alternatives are not appropriate.

How long does Zepbound prior authorization take? Standard prior authorization decisions are required within 72 hours to 10 business days depending on the plan. Expedited prior authorization (for urgent situations) is required within 24 to 72 hours. Average processing time is 3 to 7 business days.

What happens if I can't afford my Tier 3 copay for Zepbound? You have three options: request a tier exception to lower your cost-sharing, apply for manufacturer copay assistance (Eli Lilly offers a savings card that reduces copays to $25 for commercially insured patients, subject to eligibility), or switch to compounded tirzepatide cash-pay.

Does the Zepbound savings card work with insurance? The Zepbound savings card reduces your copay to $25 per month for up to 13 fills if you have commercial insurance and your plan covers Zepbound. It does not work with Medicare, Medicaid, or if your insurance excludes Zepbound entirely.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Express Scripts. 2025 Drug Trend Report. Express Scripts. 2025.
4. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
5. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Requirements 2026. CMS. 2026.
6. America's Health Insurance Plans. Prior Authorization and Utilization Management Survey. AHIP. 2025.
7. U.S. Food and Drug Administration. Drug Shortages Database. FDA. 2026.
8. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
9. Eli Lilly and Company. Zepbound Prescribing Information. Lilly. 2023.
10. UnitedHealthcare. Commercial Formulary Q1 2026. UHC. 2026.
11. Anthem Blue Cross Blue Shield. Prescription Drug List 2026. Anthem. 2026.
12. Aetna CVS Health. Pharmacy Clinical Policy Bulletins: GLP-1 Receptor Agonists. Aetna. 2026.
13. Congressional Budget Office. The Inflation Reduction Act and Prescription Drug Pricing. CBO. 2025.
14. National Association of Insurance Commissioners. Model Regulation for Prescription Drug Formulary Changes. NAIC. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.